人民财讯9月18日电，泰恩康（301263）9月18日晚间公告，全资子公司安徽泰恩康制药有限公司于近日 收到国家药品监督管理局签发的甲磺酸沙非胺片境内生产药品注册上市许可申请《受理通知书》。甲磺 酸沙非胺片是一种选择性抑制B型单胺氧化酶(MAO-B)抑制剂，主要用于治疗成年特发性帕金森氏病 (PD)患者，作为稳定剂量的左旋多巴(L-dopa)单独或与其他PD治疗联合的附加疗法，用于中晚期波动患 者。 ...

格隆汇9月18日丨泰恩康(301263.SZ)公布，全资子公司安徽泰恩康制药有限公司于近日收到国家药品监 督管理局（简称"国家药监局"）签发的甲磺酸沙非胺片境内生产药品注册上市许可申请《受理通知 书》，国家药监局根据《中华人民共和国行政许可法》第三十二条的规定，对上述药品的药品注册上市 许可申请进行了审查，决定予以受理。甲磺酸沙非胺片是一种选择性抑制B型单胺氧化酶（MAO-B）抑 制剂，主要用于治疗成年特发性帕金森氏病（PD）患者，作为稳定剂量的左旋多巴（L-dopa）单独或 与其他PD治疗联合的附加疗法，用于中晚期波动患者。 ...

格隆汇9月18日丨泰恩康(301263.SZ)公布，全资子公司安徽泰恩康制药有限公司于近日收到国家药品监 督管理局（简称"国家药监局"）签发的甲磺酸沙非胺片境内生产药品注册上市许可申请《受理通知 书》，国家药监局根据《中华人民共和国行政许可法》第三十二条的规定，对上述药品的药品注册上市 许可申请进行了审查，决定予以受理。甲磺酸沙非胺片是一种选择性抑制B型单胺氧化酶（MAO-B）抑 制剂，主要用于治疗成年特发性帕金森氏病（PD）患者，作为稳定剂量的左旋多巴（L-dopa）单独或 与其他PD治疗联合的附加疗法，用于中晚期波动患者。 ...

证券代码：301263 证券简称：泰恩康 公告编号：2025-066 广东泰恩康医药股份有限公司 审核结论：根据《中华人民共和国行政许可法》第三十二条的规定，经审 查，决定予以受理。 关于全资子公司收到药品注册受理通知书的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 广东泰恩康医药股份有限公司（以下简称"公司"）全资子公司安徽泰恩 康制药有限公司于近日收到国家药品监督管理局（以下简称"国家药监局"） 签发的甲磺酸沙非胺片境内生产药品注册上市许可申请《受理通知书》，国家 药监局根据《中华人民共和国行政许可法》第三十二条的规定，对上述药品的 药品注册上市许可申请进行了审查，决定予以受理。现将相关情况公告如下： 一、申请注册药品的基本情况 受理号：CYHS2503455、CYHS2503456 药品名称：甲磺酸沙非胺片 申请事项：境内生产药品注册上市许可 许可药品注册分类：化学药品 4 类 规格：50mg、100mg 申请人：安徽泰恩康制药有限公司 二、药品相关情况简介 甲磺酸沙非胺片是一种选择性抑制 B 型单胺氧化酶（MAO-B）抑制剂，主 要用于治疗成年特 ...

Group 1 - The core viewpoint of the news is that 泰恩康's stock has experienced fluctuations, with a notable decline of 2.13% on September 18, 2023, and a significant increase of 145.49% year-to-date [1] - As of September 18, 2023, 泰恩康's stock price is 36.31 CNY per share, with a total market capitalization of 15.45 billion CNY [1] - The company has seen a net outflow of main funds amounting to 20.34 million CNY, with large orders showing a buy of 41.42 million CNY and a sell of 44.88 million CNY [1] Group 2 - For the first half of 2023, 泰恩康 reported a revenue of 34.7 million CNY, a year-on-year decrease of 12.23%, and a net profit attributable to shareholders of 37.08 million CNY, down 56.75% year-on-year [2] - The company has distributed a total of 460 million CNY in dividends since its A-share listing, with 377 million CNY distributed over the past three years [3] Group 3 - 泰恩康's main business segments include pharmaceutical agency (65.16%), pharmaceutical manufacturing (31.70%), and pharmaceutical technology services and technology transfer (2.97%) [1] - The company is categorized under the pharmaceutical and biological industry, specifically in chemical pharmaceuticals and chemical preparations [1]

Group 1 - The core viewpoint of the news is that 泰恩康's stock has experienced fluctuations, with a current price of 37.85 yuan per share and a market capitalization of 16.105 billion yuan, despite a significant year-to-date increase of 155.90% [1] - The company has seen a net outflow of main funds amounting to 30.06 thousand yuan, with large orders showing a buy of 829.73 thousand yuan and a sell of 737.58 thousand yuan [1] - 泰恩康's main business revenue composition includes 65.16% from pharmaceutical agency, 31.70% from pharmaceutical manufacturing, and 2.97% from pharmaceutical technology services and technology transfer [1] Group 2 - As of June 30, 泰恩康 had 10,900 shareholders, a decrease of 33.05% from the previous period, with an average of 27,747 circulating shares per person, an increase of 49.36% [2] - For the first half of 2025, 泰恩康 reported operating revenue of 34.7 million yuan, a year-on-year decrease of 12.23%, and a net profit attributable to shareholders of 37.08 million yuan, down 56.75% year-on-year [2] - Since its A-share listing, 泰恩康 has distributed a total of 460 million yuan in dividends, with 377 million yuan distributed over the past three years [3]

证券代码：301263 证券简称：泰恩康 公告编号：2025-065 广东泰恩康医药股份有限公司 关于参加广东辖区 2025 年投资者网上集体接待日暨辖 区上市公司中报业绩说明会活动的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 为进一步加强与投资者的交流沟通，广东泰恩康医药股份有限公司（以下简 称"公司"）将参加由中国证券监督管理委员会广东监管局、广东上市公司协会 联合举办的"向新提质 价值领航——2025 年广东辖区投资者网上集体接待日暨 辖区上市公司中报业绩说明会"，现将相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net）参与本次互动交流，活动时间为 2025 年 9 月 19 日（周五） 15:30-17:00。 届时，公司董事长、总经理郑汉杰先生，公司董事、副总经理兼董事会秘书 李挺先生，财务总监周桂惜女士将通过网络互动形式，在信息披露允许的范围内 与投资者就公司经营情况及发展战略等方面进行沟通与交流。欢迎广大投资者积 极参与。 特此公告。 广东泰恩康医药股份有限公司 董事会 ...

Company Overview - Taiankang Pharmaceutical Co., Ltd. is located in Shantou, Guangdong Province, established on January 22, 1999, and listed on March 29, 2022 [1] - The company's main business includes the agency operation, research and development, production, and sales of pharmaceutical products, medical devices, and health materials, as well as providing pharmaceutical technology services and technology transfer [1] - The revenue composition is as follows: pharmaceutical agency 65.16%, pharmaceutical manufacturing 31.70%, pharmaceutical technology services and technology transfer 2.97%, and others 0.17% [1] Stock Performance - As of September 16, Taiankang's stock price increased by 2.05%, reaching 38.37 CNY per share, with a trading volume of 215 million CNY and a turnover rate of 1.86%, resulting in a total market capitalization of 16.326 billion CNY [1] - Year-to-date, the stock price has risen by 159.41%, with a 2.81% increase over the last five trading days, 7.78% over the last 20 days, and 9.79% over the last 60 days [1] Financial Performance - As of June 30, Taiankang reported a decrease in revenue to 347 million CNY for the first half of 2025, a year-on-year decline of 12.23%, and a net profit attributable to shareholders of 37.08 million CNY, down 56.75% year-on-year [2] - The number of shareholders decreased by 33.05% to 10,900, while the average circulating shares per person increased by 49.36% to 27,747 shares [2] Dividend Information - Since its A-share listing, Taiankang has distributed a total of 460 million CNY in dividends, with 377 million CNY distributed over the past three years [3]

Group 1 - The company, Taiankang (301263), announced the election of Mr. Chen Chun as the employee director of the fifth board of directors during the employee representative meeting held on September 10, 2025 [1]

国浩律师（深圳）事务所 法律意见书 一、本次股东大会的召集与召开程序 经本所律师核查，2025年8月19日，公司召开第五届董事会第十次会议，审议通 过《关于召开公司2025年第二次临时股东大会的议案》，决定于2025年9月10日（星 期三）下午15:00召开本次股东大会。 国浩律师（深圳）事务所 关于广东泰恩康医药股份有限公司 2025年第二次临时股东大会法律意见书 致：广东泰恩康医药股份有限公司 国浩律师（深圳）事务所（以下简称"本所"）接受广东泰恩康医药股份有限公 司（以下简称"公司"）的委托，指派张韵雯律师、李德齐律师（以下简称"本所律 师"）出席公司2025年第二次临时股东大会（以下简称"本次股东大会"或"本次会 议"），对本次股东大会的合法性进行见证。本所律师根据《中华人民共和国公司法》 （以下简称"《公司法》"）《上市公司股东会规则》等法律、法规和规范性文件以 及《广东泰恩康医药股份有限公司章程》（以下简称"《公司章程》"）的规定，就 公司本次股东大会的召集、召开程序、出席会议人员的资格、召集人的资格、表决程 序和表决结果等有关事宜出具本法律意见书。 在本法律意见书中，本所律师仅对本次股东大会的召 ...